Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pinometostat - Epizyme

Drug Profile

Pinometostat - Epizyme

Alternative Names: EPZ-5676

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epizyme
  • Class Antineoplastics; Benzimidazoles; Cyclobutanes; Furans; Purines; Small molecules
  • Mechanism of Action DOT1L protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute biphenotypic leukaemia

Most Recent Events

  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 10 Oct 2018 National Cancer Institute plans a phase Ib/II trial for Acute myeloid leukaemia (First-line therapy, Newly diagnosed, Combination) with MLL rearrangement (NCT03724084)
  • 10 Oct 2018 National Cancer Institute plans a phase I/II trial Acute myeloid leukaemia (Second-line therapy or greater, Newly diagnosed) in November 2018 (NCT03701295)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top